UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): April 29, 2021
NeuBase Therapeutics, Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware | | 001-35963 | | 46-5622433 |
(State or Other Jurisdiction
of Incorporation) | | (Commission
File Number) | | (I.R.S. Employer
Identification No.) |
| 350 Technology Drive, Pittsburgh, PA | 15219 |
| (Address of Principal Executive Offices) | (Zip Code) |
| | (646) 450-1790 | |
| (Registrant's Telephone Number, Including Area Code) |
| | N/A | |
| (Former Name or Former Address, if Changed Since Last Report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, par value $0.0001 per share | NBSE | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
NeuBase Therapeutics, Inc. (the “Company”) is filing this Current Report on Form 8-K to correct an error appearing on page S-5 of the prospectus supplement, dated April 22, 2021, filed by the Company on April 23, 2021 relating to the Company’s PATrOL™-enabled NT0200 program currently in preclinical development for the treatment of DM1. The Company expects to initiate scale up and toxicology activities for such program beginning in the middle of calendar year 2021 rather than calendar year 2022 as reflected therein.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | NEUBASE THERAPEUTICS, INC.
(Registrant) |
| | |
| Date: April 30, 2021 | By: | /s/ Sam Backenroth |
| | | Sam Backenroth |
| | | Chief Financial Officer |
